19/08/2019 – AB Science announces the success of a private placement
12/08/2019 – AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.
05/08/2019 – AB Science provides an update on its masitinib clinical program.
02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.
22/07/2019 – AB Science Corporate Presentation – July 2019
09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019
08/07/2019 – AB Science web conference presentation
08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure
04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.
26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease